Biohaven Pharmaceutical Holding Co (NASDAQ: BHVN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both biotechnology & medical research – nec companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Valuation & Earnings

This table compares Biohaven Pharmaceutical Holding Co and Enanta Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Biohaven Pharmaceutical Holding Co N/A N/A N/A ($5.47) -5.38
Enanta Pharmaceuticals $88.27 million 10.96 $21.66 million ($1.08) -46.93

Enanta Pharmaceuticals has higher revenue and earnings than Biohaven Pharmaceutical Holding Co. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical Holding Co, indicating that it is currently the more affordable of the two stocks.


This table compares Biohaven Pharmaceutical Holding Co and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Biohaven Pharmaceutical Holding Co N/A -267.45% -112.36%
Enanta Pharmaceuticals -51.85% -7.74% -7.39%

Institutional & Insider Ownership

66.2% of Enanta Pharmaceuticals shares are held by institutional investors. 9.3% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Biohaven Pharmaceutical Holding Co and Enanta Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biohaven Pharmaceutical Holding Co 0 0 5 0 3.00
Enanta Pharmaceuticals 0 1 3 0 2.75

Biohaven Pharmaceutical Holding Co presently has a consensus price target of $40.80, indicating a potential upside of 38.59%. Enanta Pharmaceuticals has a consensus price target of $45.25, indicating a potential downside of 10.71%. Given Biohaven Pharmaceutical Holding Co’s stronger consensus rating and higher possible upside, equities analysts clearly believe Biohaven Pharmaceutical Holding Co is more favorable than Enanta Pharmaceuticals.


Enanta Pharmaceuticals beats Biohaven Pharmaceutical Holding Co on 6 of the 10 factors compared between the two stocks.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with's FREE daily email newsletter.